Cargando…
KRAS(G12C)–AMG 510 interaction dynamics revealed by all-atom molecular dynamics simulations
The first KRAS(G12C) targeting inhibitor in clinical development, AMG 510, has shown promising antitumor activity in clinical trials. On the molecular level, however, the interaction dynamics of this covalently bound drug–protein complex has been undetermined. Here, we disclose the interaction dynam...
Autor principal: | Pantsar, Tatu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7371895/ https://www.ncbi.nlm.nih.gov/pubmed/32686745 http://dx.doi.org/10.1038/s41598-020-68950-y |
Ejemplares similares
-
Understanding the influence of AMG 510 on the structure of KRAS(G12C) empowered by molecular dynamics simulation
por: Li, Yu, et al.
Publicado: (2022) -
Spotlight on Sotorasib (AMG 510) for KRAS(G12C) Positive Non-Small Cell Lung Cancer
por: Zhang, Shannon S, et al.
Publicado: (2021) -
Mechanistic insights into the clinical Y96D mutation with acquired resistance to AMG510 in the KRAS(G12C)
por: Zhuang, Haiming, et al.
Publicado: (2022) -
The current understanding of KRAS protein structure and dynamics
por: Pantsar, Tatu
Publicado: (2019) -
Assessment of mutation probabilities of KRAS G12 missense mutants and their long-timescale dynamics by atomistic molecular simulations and Markov state modeling
por: Pantsar, Tatu, et al.
Publicado: (2018)